What is the 13F Pro Quality Score for OPRX?

13F Pro ranks OptimizeRx Corp (OPRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View OPRX's current score at https://13fpro.ai/research/OPRX (free sign-up required for the full ranking).

Which hedge funds own the most OPRX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of OPRX include Whetstone Capital Advisors,, BlackRock,, ROYCE & ASSOCIATES. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/OPRX as soon as new 13F filings post.

Where does 13F Pro source OPRX data?

All OptimizeRx Corp fundamentals and ownership data come directly from SEC EDGAR. OptimizeRx Corp files with the SEC under CIK 1448431. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is OPRX in?

OptimizeRx Corp (OPRX) is classified in the Industrials sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/industrials.

How often is OPRX research updated on 13F Pro?

OPRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

OptimizeRx Corp(OPRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Industrials →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1448431 OPRX stock profile & AI dashboard →

13F Pro Quality Score

51.3/100

Rank #1,406 of 2,879 stocksTOP 50%

View Industrials peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

84.1/100

Profitability

53.1/100

Balance Sheet

34.8/100

Earnings Quality

30.0/100

Free Cash Flow

66.6/100

Institutional Flow

68.8/100

Revenue Scale

17.3/100

Dilution Risk

22.5/100

OPRX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for OptimizeRx Corp (OPRX), a Industrials sector company. 13F Pro's AI-powered ranking engine scores OPRX at 51.3/100 on a 32-signal composite quality model, placing it at rank #1,406 of 2,879 stocks — the top half of the AI-ranked universe. OPRX scores in the top quartile across revenue growth (84.1). Areas of concern include revenue scale (17.3) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 22.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), OptimizeRx Corp reports quarterly revenue of $19.8M, net income of $-495.0K, free cash flow of $-488.0K. Top institutional holders of OPRX by reported 13-F value include Whetstone Capital Advisors,, BlackRock,, ROYCE & ASSOCIATES, based on the most recent SEC filings. OPRX trades on the Nasdaq exchange and files with the SEC under CIK 1448431. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OPRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for OptimizeRx Corp directly from SEC EDGAR. OptimizeRx Corp's 13F Pro composite quality score has ranged between 8 and 54 since 2021, currently 51.3 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about OptimizeRx Corp

Quirks, history, and lore behind OPRX — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap U.S. company operating at the intersection of healthcare technology and digital communications, listed on Nasdaq.
2
The Numbers
Annual revenue in the range of $60–80 million — not a giant, but it serves an outsized slice of the physician-facing digital ad market.
3
The History
Founded in the early 2000s, it carved out a niche delivering real-time clinical messaging to doctors inside the electronic health record workflow — before most pharma companies knew that was possible.
4
The Secret
Its platform embeds pharmaceutical brand messaging directly into the tools clinicians use at the point of care, so the "ad" shows up right when a prescription decision is being made.
5
The Lore
Its core customers are life sciences and pharma companies trying to reach hard-to-find specialists — think oncologists and cardiologists — without a sales rep ever walking through a hospital door.
6
The Giveaway
Its very name is a promise: help pharma optimize how they reach doctors — and its ticker, a tidy four letters, is basically a compressed version of that promise.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$19.8M

Net Income

Q1 2026

$-495.0K

Free Cash Flow

Q1 2026

$-488.0K

ROIC

Q1 2026

0.3%

D/E Ratio

Q1 2026

0.20

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+18.8% YoY

$109.4MFY 2025

FY22 $62.5MFY23 $71.5MFY24 $92.1MFY25 $109.4M

Net Income

+125.5% YoY

$5.1MFY 2025

FY22 $-11.4MFY23 $-17.6MFY24 $-20.1MFY25 $5.1M

Operating Income

+185.3% YoY

$11.7MFY 2025

FY22 $-12.3MFY23 $-26.4MFY24 $-13.7MFY25 $11.7M

EPS (Diluted)

+124.5% YoY

$0.27FY 2025

FY22 $-0.64FY23 $-1.03FY24 $-1.10FY25 $0.27

Total Assets

+3.4% YoY

$176.9MFY 2025

FY22 $134.7MFY23 $183.4MFY24 $171.2MFY25 $176.9M

Total Debt

-15.8% YoY

$30.5MFY 2025

FY22 —FY23 $40.3MFY24 $36.3MFY25 $30.5M

Op. Cash Flow

+282.8% YoY

$18.7MFY 2025

FY22 $10.7MFY23 $-7.2MFY24 $4.9MFY25 $18.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$109.4M +18.8%	$92.1M +28.8%	$71.5M +14.5%	$62.5M +1.9%	$61.3M +41.5%	$43.3M
Net Income	$5.1M +125.5%	$-20.1M -14.5%	$-17.6M -53.6%	$-11.4M -3125.4%	$378.1K +117.1%	$-2.2M
Operating Income	$11.7M +185.3%	$-13.7M +48.1%	$-26.4M -114.8%	$-12.3M -3503.7%	$361.1K +116.9%	$-2.1M
EPS (Diluted)	$0.27 +124.5%	$-1.10 -6.8%	$-1.03 -60.9%	$-0.64 -3300.0%	$0.02 +113.3%	$-0.15
Total Assets	$176.9M +3.4%	$171.2M -6.7%	$183.4M +36.2%	$134.7M -4.5%	$141.0M +133.7%	$60.3M
Total Debt	$30.5M -15.8%	$36.3M -9.9%	$40.3M	—	—	—
Operating Cash Flow	$18.7M +282.8%	$4.9M +167.5%	$-7.2M -168.0%	$10.7M +1367.4%	$726.0K +111.5%	$-6.3M

AI Insight: OPRX Financial Trends

OptimizeRx swung to profitability in late 2025 but revenue collapsed 37% in Q1 2026, signaling demand cliff or execution issues.

• Operating income inflected from negative in Q1–Q3 2025 to $9M in Q4 2025, then returned to breakeven in Q1 2026.

• Total debt declined 37% from $41M in Q2 2024 to $26M in Q1 2026, improving leverage profile.

• Q1 2026 revenue dropped to $20M, the lowest in eight quarters, erasing H2 2025 momentum.

⚠ Operating cash flow turned negative in Q1 2026 after 6 consecutive positive quarters; validate sustainability.

⚠ Revenue volatility extreme (Q3 2024 spike to $57M, now $20M); underlying business model clarity needed.

AI Insight: OPRX Ratio Trends

OptimizeRx swung to profitability in 2025 but Q1 2026 shows sharp deterioration across all returns metrics.

• Operating margin rebounded from -9.6% in Q1 2025 to 26.6% in Q4 2025, then collapsed to 2.0% in Q1 2026.

• ROIC improved from -5.5% (Q1 2025) to 21.6% (Q4 2025), but fell to 1.0% in latest quarter.

• Leverage declined steadily: D/E ratio dropped from 0.34 (Q2–Q3 2024) to 0.20 (TTM and Q1 2026).

⚠ Q1 2026 profitability collapse across OpMargin, NPM, ROE, ROA, ROIC — steepest single-quarter drop since Q1 2025.

⚠ Negative NPM (-2.5%) in Q1 2026 signals operational earnings weakness despite positive operating margin.

Get alerted when OPRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for OptimizeRx Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of OPRX

Whetstone Capital Advisors, LLC
$9.5M1,508,303 sh
BlackRock, Inc.
$7.3M1,163,501 sh
ROYCE & ASSOCIATES LP
$5.6M888,030 sh
Parkman Healthcare Partners LLC
$4.6M729,369 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.3M685,449 sh
KENNEDY CAPITAL MANAGEMENT LLC
$4.1M656,258 sh
BLAIR WILLIAM & CO/IL
$3.9M614,992 sh
RICE HALL JAMES & ASSOCIATES, LLC
$3.8M601,921 sh
DIMENSIONAL FUND ADVISORS LP
$3.5M563,570 sh
STATE STREET CORP
$3.0M477,780 sh

Fund	Value	Shares
Whetstone Capital Advisors, LLC	$9.5M	1,508,303
BlackRock, Inc.	$7.3M	1,163,501
ROYCE & ASSOCIATES LP	$5.6M	888,030
Parkman Healthcare Partners LLC	$4.6M	729,369
VANGUARD CAPITAL MANAGEMENT LLC	$4.3M	685,449
KENNEDY CAPITAL MANAGEMENT LLC	$4.1M	656,258
BLAIR WILLIAM & CO/IL	$3.9M	614,992
RICE HALL JAMES & ASSOCIATES, LLC	$3.8M	601,921
DIMENSIONAL FUND ADVISORS LP	$3.5M	563,570
STATE STREET CORP	$3.0M	477,780

More Industrials Companies

View all Industrials →

AADX

Applied Aerospace & Defense, Inc.

AAL

American Airlines Group Inc.

AAON

AAON, INC.

ABM

ABM INDUSTRIES INC /DE/

ACA

Arcosa, Inc.

ACHR

Archer Aviation Inc.

ACLS

AXCELIS TECHNOLOGIES INC

ACMR

ACM Research, Inc.

Put OPRX on your watchlist

Track score changes the day OptimizeRx Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is OPRX a good stock to buy?

13F Pro's AI-powered analysis of OptimizeRx Corp (OPRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Industrials sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OPRX are available on the OPRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own OPRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OPRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of OptimizeRx Corp's investment landscape.